Close Menu

NEW YORK – OncoDNA and myNEO said on Wednesday that they have partnered to develop personalized, mRNA-based vaccines to treat advanced cancer patients.

Within the collaboration, the Belgium-based companies will use their respective technologies —OncoDNA's whole-genome and whole-transcriptome sequencing capabilities, and myNEO's artificial intelligence and bioinformatics capabilities — to identify targetable neoantigens in individual cancer patients and design mRNA-based vaccines that instruct their immune systems to go after those targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.